Navigation Links
EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Date:8/19/2007

th several pain therapies in late-stage clinical trials, and a lead oncology compound (for acute myeloid leukemia, or AML) with demonstrated efficacy in a Phase III trial; a marketing authorization application for this compound has been submitted in Europe. EpiCept is based in Tarrytown, N.Y., and its research and development team in San Diego is pursuing a drug discovery program focused on novel approaches to apoptosis.

Forward-Looking Statements

This news release and any oral statements made with respect to the information contained in this news release, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements which express plans, anticipation, intent, contingency, goals, targets, future development and are otherwise not statements of historical fact. These statements are based on EpiCept's current expectations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results or developments to differ materially include: the risk that Ceplene will not receive regulatory approval or marketing authorization in the EU or that Ceplene, if approved, will not achieve significant commercial success, the risk that Myriad's development of Azixa will not be successful, the risk that Azixa will not receive regulatory approval or achieve significant commercial success, the risk that we will not receive any significant payments under our agreement with Myriad, the risk that the development of our other apoptosis product candidates will not be successful, the risk that our ASAP technology will not yield any successful product candidates, the risk that clinical trials for NP-1 will not be successful, that NP-1 will not receive regulatory approval or achieve significant
'/>"/>

SOURCE EpiCept Corporation

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014 EvoDerma ’s NOOME Anti-Aging ... rejuvenating device now comes with a second treatment cup to ... , The new cup is thinner on the edges for ... target rough, thin and uneven surfaces on the face, neck ... a stimulating treatment on areas such as the cheeks and ...
(Date:7/10/2014)... , July 10, 2014 /PRNewswire-iReach/ -- ... and interpretation, today announced an agreement with ... analytics for Lineagen,s NextStep Dx PLUS.  ... neurodevelopmental and neurological disorders, currently offers FirstStep ... (CMA) testing service used by healthcare providers ...
(Date:7/10/2014)... 17, 2014 Using microscopic polymer light resonators ... researchers at MIT,s Quantum Photonics Laboratory have developed ... the parts-per-billion range. Optical sensors are ideal for ... signal-to-noise ratio, compact, lightweight nature, and immunity to ... had been developed before, the MIT team conceived ...
(Date:7/10/2014)... Not even geckos and spiders can sit upside down forever. ... have demonstrated this in an article just published in ... industrial benefit. , Geckos and spiders that seem to be ... have fascinated researchers worldwide for many years. We will soon ... same way as the gecko,s foot. But the fact is, ...
Breaking Biology Technology:Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Swell new sensors 2Even geckos can lose their grip 2
... A relatively fast, easy and inexpensive technique for ... self-assemble into one-, two- and even three-dimensional macroscopic ... researchers with the U.S. Department of Energy (DOE),s ... should enable more effective use of nanorods in ...
... Laboratories, Inc. (OTCBB: UGNE) today announced that it ... Award in the Industry Achievement category in recognition of ... of peptides.  This year,s DDP Award ... including leading scientists, pharmaceutical executives and drug delivery key ...
... Mass. and TORONTO, Feb. 1, 2012  Generex Biotechnology ... owned subsidiary, Antigen Express, Inc., has been awarded ... for the development of immunotherapeutic vaccines.  A number ... in clinical development.  The patent helps to secure ...
Cached Biology Technology:Self-assembling nanorods: Berkeley Lab researchers obtain 1-, 2- and 3-D nanorod arrays and networks 2Self-assembling nanorods: Berkeley Lab researchers obtain 1-, 2- and 3-D nanorod arrays and networks 3Self-assembling nanorods: Berkeley Lab researchers obtain 1-, 2- and 3-D nanorod arrays and networks 4Unigene Receives 2012 Drug Delivery Partnerships Industry Achievement Award 2Unigene Receives 2012 Drug Delivery Partnerships Industry Achievement Award 3Unigene Receives 2012 Drug Delivery Partnerships Industry Achievement Award 4Unigene Receives 2012 Drug Delivery Partnerships Industry Achievement Award 5Generex Announces Patent Award for its Core Vaccine Technologies in Japan 2Generex Announces Patent Award for its Core Vaccine Technologies in Japan 3Generex Announces Patent Award for its Core Vaccine Technologies in Japan 4
(Date:7/11/2014)... The Chinese University of Hong Kong, BGI and other ... to salt tolerance, with implication for improving this important ... online in Nature Communications provides an effective ... , Soybean is an important crop for the world. ... less genetic diversities than their wild counterparts. Among the ...
(Date:7/11/2014)... the Max Planck Institute for Medical Research in Heidelberg, ... photosynthesis, the process by which the Earth first gained ... which is therefore crucial for all higher forms of ... first direct visualization of a crucial event in the ... protein complex, photosystem II, splits water into hydrogen and ...
(Date:7/11/2014)... July 11, 2014 The increased risk of kidney ... in resuscitation fluids reflects the mass of HES molecules, ... , official journal of the International Anesthesia Research Society ... the harmful effect of HES on cultured human renal ... Dr Christian Wunder and colleagues of University Hospital Wrzburg, ...
Breaking Biology News(10 mins):BGI reports a novel gene for salt tolerance found in wild soybean 2A first direct glimpse of photosynthesis in action 2In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2
... more about climate change, floods, volcanoes, ground water and more ... is just around the corner how many of you ... minerals make up your holiday lights? In this edition of ... is providing clues about future changes and about recent estimates ...
... are repairing the human body in ways never imagined ... an increasing population of patients who are newly susceptible ... become a formidable clinical opponent, and foremost among them ... new text from ASM Press. "This volume ...
... WA This Christmas season, think twice about spending ... tree. The good, old-fashioned methodkeeping your tree in a ... keep your tree green and healthy. Researchers have determined ... trees; in fact, in several cases the chemical retardants ...
Cached Biology News:USGS Science Picks 2USGS Science Picks 3USGS Science Picks 4USGS Science Picks 5USGS Science Picks 6USGS Science Picks 7USGS Science Picks 8USGS Science Picks 9USGS Science Picks 10USGS Science Picks 11New text focuses on formidable opportunistic fungus 2Flame retardants prove ineffective on fresh-cut Christmas trees 2
... identification through targeting resequencing. This ... assay validation/optimization, high throughput PCR setup ... samples and sequence alignment and analysis.,Agencourts ... and highly accurate identification of SNP ...
... Gene/cDNA or Isolated Sequence) siRNA Test System ... for evaluation of a potential of any ... target for RNA interference (RNAi). Current computer-based ... leaving the probability of selected sequence to ...
... a is a bovine protein-free alternative to ... an aqueous solution that contains non-toxic chemicals ... pH 6.6 - 7.2. This product ... 0.02% bromonitrodioxane as a preservative. StabilGuard ...
... antigen, Monoclonal Antibody, Unconjugated ... at an assay dependent dilution. IF: ... WB: Use at an assay dependent ... Not tested in other applications. ...
Biology Products: